SCHEMBL15045589

SCHEMBL15045589

Cc1cnc2ccc3nc(C)[nH]c3c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.39
▸ CCR1 P32246 1/20 0.37
▸ CCR5 P51681 1/20 0.37
▸ CCR8 P51685 1/20 0.37
▸ PARP1 P09874 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ GAA P10253 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ GLA P06280 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ PDK2 Q15119 1/20 0.35
▸ PDK4 Q16654 1/20 0.35
▸ ACVR1 Q04771 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12327989 0.81 KDM4E (0.40) CYP1A2ALDH1A1CCR1CCR5CCR8
SCHEMBL12328107 0.79 TYMS (0.46) CYP1A2ALDH1A1PARP1KDM4EHSD17B10
SCHEMBL15045567 0.78 CYP1A2 (0.41) CYP1A2ALDH1A1CCR1CCR5CCR8
SCHEMBL13561686 0.78 CCR1 (0.58) CYP1A2ALDH1A1CCR1CCR5CCR8
SCHEMBL9539910 0.77 CYP1A2 (0.52) CYP1A2CCR1CCR5CCR8PARP1
SCHEMBL18658895 0.75 PIK3CA (0.41) —
SCHEMBL13561566 0.75 CHEK1 (0.42) PARP1
SCHEMBL13561693 0.75 IL5 (0.41) CYP1A2ALDH1A1PARP1KDM4EHSD17B10
SCHEMBL13383928 0.74 ALDH1A1 (0.48) ALDH1A1PARP1KDM4EHSD17B10LMNA
SCHEMBL311958 0.74 PARP1 (0.51) CYP1A2ALDH1A1PARP1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796705-B2 Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases MERCK SHARP & DOHME CORP. (US) 2017-10-24 — — US disclosed
US-20170008879-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2017-01-12 — — US disclosed
US-20130156731-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS SCHERING CORPORATION 2013-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130156731-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS HAVCR2, ELOC, ZC3HAV1 CYP1A2 364/4885ALDH1A1 578/4885CCR1 420/4885
US-20170008879-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES ZC3HAV1, HAVCR2, ZC3HAV1L CYP1A2 1816/4885ALDH1A1 3470/4885CCR1 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback